Corporate
Biotrial strengthens its partnership with Pareann Biotechnologies to expand Preclinical and Clinical capabilities
Already collaborating on the development of a novel preclinical lung cancer model combining a controlled microbiome, a humanized immune system, and tumor cells derived from patients (MESHCAP project), Biotrial and Parean are expanding their collaboration to support the development of immunotherapies, cell therapies, and vaccines in oncology and autoimmune diseases.
Through this partnership, Biotrial will leverage Parean’s expertise in immunology bioassays, single-cell omics, and omics-driven data science, offering sponsors a comprehensive and translational approach.
This strengthened collaboration brings expertise in:
- Non-clinical development, including target scoring, new modality characterization, and TCR lead generation
- Clinical studies, with advanced cell therapy characterization and highcontent
- readouts
- Biometrics and Data Science services
- Bioanalytical services
Together, Biotrial and Parean aim to advance translational research and drive
innovation across the development of complex therapeutic modalities.
About Biotrial
Founded in 1989, Biotrial, leading full service CRO, provides solutions from preclinical to clinical studies, bringing a wealth of expertise to the study feasibility and design process. Biotrial’s services are available as full services or stand-alone contracts including: Preclinical Pharmacology, Clinical Development, Data Management, Core Lab services with EEG & ECG, imaging, Data Science and Bioanalysis.
About Parean Biotechnologies
Parean Biotechnologies specializes in advanced immunology and omics technologies, including immunology bioassays, single-cell omics, and data science. The company supports the development of innovative therapies, particularly in oncology and autoimmune diseases, through cutting-edge scientific expertise.
